HCPCS Level II code J7210 describes an injection of recombinant factor VIII (antihemophilic factor, recombinant) branded as Afstyla, billed per 1 international unit (IU); this represents administration of a clotting factor concentrate typically used to treat or prevent bleeding in individuals with hemophilia A, delivered as an infused medication and commonly provided in outpatient infusion centers, hospital outpatient departments, or specialty infusion clinics.

For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only), Antibody-Drug Conjugates.